Craneware Plc (GB:CRW)
LSE:CRW
Want to see GB:CRW full AI Analyst Report?
Top Page
Craneware
(LSE:CRW)
Select Model
Select Model
Rating:61Neutral
Price Target:
1,610.00 p
â–¼(-27.80% Downside)
Action:ReiteratedDate:02/24/26
The score is driven primarily by solid financial performance (strong margins and a low-debt balance sheet), but it is meaningfully weighed down by weak technical momentum (price below key moving averages with negative MACD) and a relatively high P/E that limits valuation support despite the dividend yield.
Positive Factors
High Gross Margins
Sustained gross margins above 85% indicate strong unit economics and pricing power in software and services. High gross margins create durable room to fund R&D, sales and implementation, while insulating operating profitability from moderate revenue volatility over the next 2-6 months.
Negative Factors
Declining Free Cash Flow Growth
A 13.4% drop in free cash flow growth reduces internally available funds for reinvestment, dividends or M&A. If the decline persists it could force trade-offs between growth spending and shareholder returns and weaken resilience to prolonged investment cycles.
Read all positive and negative factors
Positive Factors
Negative Factors
High Gross Margins
Sustained gross margins above 85% indicate strong unit economics and pricing power in software and services. High gross margins create durable room to fund R&D, sales and implementation, while insulating operating profitability from moderate revenue volatility over the next 2-6 months.
Read all positive factors
Craneware (CRW) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£521.43M
Dividend Yield1.66%
Average Volume (3M)71.71K
Price to Earnings (P/E)22.6
Beta (1Y)0.72
Revenue Growth3.46%
EPS Growth46.25%
CountryUK
Employees747
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)0.63
Shares Outstanding34,530,167
10 Day Avg. Volume64,377
30 Day Avg. Volume71,707
Financial Highlights & Ratios
PEG Ratio0.76
Price to Book (P/B)3.07
Price to Sales (P/S)5.04
P/FCF Ratio17.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.2
Revenue Forecast (FY)£226.01M
Craneware Business Overview & Revenue Model
Company Description
Craneware plc, together with its subsidiaries, develops, licenses, and supports computer software for the healthcare industry in the United States. The company provides solutions, such as Chargemaster Toolkit, an automated software-as-a-service (S...
How the Company Makes Money
Craneware primarily makes money by selling its healthcare revenue-cycle and financial-performance software to hospital providers under recurring subscription (SaaS) arrangements, typically priced via contract-based fees tied to access/usage and th...
Craneware Financial Statement Overview
Summary
Income Statement
75
Positive
Balance Sheet
80
Positive
Cash Flow
70
Positive
| Breakdown | TTM | Jun 2025 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 211.84M | 205.66M | 174.02M | 165.54M | 75.58M | 71.49M |
| Gross Profit | 165.28M | 179.27M | 148.44M | 142.37M | 70.20M | 66.97M |
| EBITDA | 47.60M | 38.80M | 51.60M | 47.54M | 18.48M | 23.87M |
| Net Income | 22.52M | 19.66M | 9.23M | 9.41M | 12.90M | 16.84M |
Balance Sheet | ||||||
| Total Assets | 525.76M | 551.06M | 576.98M | 568.79M | 311.60M | 115.76M |
| Cash, Cash Equivalents and Short-Term Investments | 40.96M | 55.92M | 78.54M | 47.16M | 235.62M | 47.85M |
| Total Debt | 26.91M | 31.65M | 86.69M | 115.52M | 2.20M | 2.96M |
| Total Liabilities | 186.25M | 213.50M | 249.13M | 235.77M | 51.32M | 47.36M |
| Stockholders Equity | 339.51M | 337.56M | 327.84M | 333.02M | 260.28M | 68.39M |
Cash Flow | ||||||
| Free Cash Flow | 9.69M | 59.41M | 83.20M | 12.93M | 13.21M | 10.96M |
| Operating Cash Flow | 10.10M | 59.90M | 98.75M | 26.96M | 23.54M | 20.67M |
| Investing Cash Flow | -15.94M | -13.98M | -15.34M | -307.32M | -10.32M | -9.71M |
| Financing Cash Flow | -25.44M | -24.58M | -53.28M | 91.90M | 174.55M | -10.72M |
Craneware Technical Analysis
Neutral
2230.00
Price Trends
1422.71
Positive
1660.19
Negative
1945.93
Negative
Market Momentum
11.51
Negative
63.79
Neutral
94.02
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:CRW, the sentiment is Neutral. The current price of 2230 is above the 20-day moving average (MA) of 1376.15, above the 50-day MA of 1422.71, and above the 200-day MA of 1945.93, indicating a neutral trend. The MACD of 11.51 indicates Negative momentum. The RSI at 63.79 is Neutral, neither overbought nor oversold. The STOCH value of 94.02 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:CRW.
Craneware Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | £46.61M | 2.68 | 8.84% | ― | -5.18% | -66.95% | |
61 Neutral | £521.43M | 22.56 | 6.65% | 1.66% | 3.46% | 46.25% | |
57 Neutral | £140.00M | -5.17 | -3.95% | ― | 31.83% | 46.59% | |
53 Neutral | £205.04M | 41.48 | 2.09% | ― | 8.46% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | £14.99M | -7.18 | -15.57% | ― | 13.32% | 55.07% | |
46 Neutral | £16.53M | -4.90 | -58.72% | ― | -9.11% | 18.91% |
* Healthcare Sector Average
GB:CRW
Craneware
1,526.00
-298.58
-16.36%
GB:COG
Cambridge Cognition Holdings
35.50
-2.00
-5.33%
GB:IXI
IXICO plc
6.88
-2.13
-23.61%
GB:KOO
Kooth
128.50
-12.50
-8.87%
GB:DXRX
Diaceutics
165.50
44.00
36.21%
GB:OPT
Optima Health PLC
188.50
2.46
1.32%
Craneware Corporate Events
Stock BuybackRegulatory Filings and Compliance
Craneware Updates Market on Share Buyback and Voting Rights
Positive
May 1, 2026
Craneware has continued to execute its share buyback programme, repurchasing tranches of ordinary shares between 23 and 29 April 2026 on AIMX and the London Stock Exchange at volume‑weighted average prices around 1,530–1,570 pence. The...
Business Operations and StrategyStock BuybackRegulatory Filings and Compliance
Craneware Tightens Free Float with Further Share Buybacks
Positive
Apr 23, 2026
Craneware has repurchased 117,395 of its own ordinary shares on the London Stock Exchange between 17 and 22 April 2026 at prices ranging from 1,486p to 1,542p, with a volume‑weighted average price of 1,512.18p. The shares, bought through Ber...
Business Operations and StrategyStock Buyback
Craneware Buys Back Shares as Treasury Holdings Rise
Positive
Apr 17, 2026
Craneware plc, a healthcare financial performance software provider listed on AIM, has continued to deploy its Trisus cloud-based analytics and revenue optimisation tools to support hospitals and health systems in improving margins and managing co...
Business Operations and Strategy
Craneware Leaves Employee Share Scheme Balances Unchanged Over Six-Month Period
Positive
Apr 15, 2026
Craneware plc reported that, for the six-month period from 16 October 2025 to 15 April 2026, no new ordinary shares were issued or allotted under its various employee share schemes, including legacy and current option, incentive, and stock purchas...
Business Operations and StrategyExecutive/Board ChangesRegulatory Filings and Compliance
Craneware Grants Share Options to Chief Legal Officer Under U.S. Employee Plan
Positive
Apr 13, 2026
Craneware plc has granted a share option over 1,004 ordinary shares to Chief Legal Officer Eric Carter under its 2018 Employee Stock Purchase Plan, at an exercise price of £11.594 per share. The option, offered on the same terms as to other U...
Business Operations and StrategyStock BuybackRegulatory Filings and Compliance
Craneware Advances Share Buyback, Updates Voting Rights Count
Positive
Apr 13, 2026
Craneware has continued its previously announced share buyback programme, repurchasing a total of 40,731 ordinary shares between 7 and 9 April 2026 on the AIM and London Stock Exchange at volume-weighted average prices around 1,384p to 1,392p. The...
Stock BuybackRegulatory Filings and Compliance
Craneware Tightens Share Capital with Treasury Stock Buyback
Neutral
Apr 8, 2026
Craneware has repurchased a series of its own ordinary shares between 31 March and 2 April 2026 under a previously announced buyback programme, executing trades on both AIMX and the London Stock Exchange at volume-weighted average prices in the lo...
Stock Buyback
Craneware Adds to Treasury Stock as Share Buyback Programme Advances
Positive
Apr 1, 2026
Craneware plc has continued to execute its previously announced share buyback programme, repurchasing a series of ordinary shares between 24 and 30 March 2026 on AIM and the London Stock Exchange at volume-weighted average prices predominantly in ...
Business Operations and StrategyStock Buyback
Craneware Continues Share Buyback, Tightening Free Float and Treasury Position
Positive
Mar 25, 2026
Craneware has repurchased 42,302 of its own ordinary shares on the London Stock Exchange as part of a previously announced share buyback programme, paying a volume-weighted average price of 1,364.95 pence. The shares will be held in treasury, leav...
Business Operations and StrategyStock Buyback
Craneware Buys Back 217,464 Shares for Treasury on AIM
Positive
Mar 23, 2026
Craneware plc has repurchased 217,464 of its own ordinary shares on AIM between 16 and 20 March 2026 at prices ranging from 1,350p to 1,440p, with a volume-weighted average price of 1,401.43p. The shares will be held in treasury, leaving 35,296,64...
Business Operations and StrategyDividends
Craneware Sets FX Rate for U.S. Dollar Interim Dividend Election
Positive
Mar 20, 2026
Craneware plc has confirmed the currency arrangements for its recently declared interim dividend, specifying that shareholders who elected to receive their payout in U.S. dollars will be paid at an exchange rate of $1.33. The clarification provide...
Business Operations and StrategyStock Buyback
Craneware launches $25m buyback to boost returns and manage dilution
Positive
Mar 16, 2026
Craneware has launched a share buyback programme of up to $25 million, authorising the repurchase of up to 3,542,956 ordinary shares through Peel Hunt, Investec and Berenberg, with the programme running until the earlier of late 2026 milestones or...
Business Operations and StrategyStock BuybackDividendsFinancial Disclosures
Craneware Posts Strong Interim Profit Growth and Launches $25m Buyback
Positive
Mar 2, 2026
Craneware reported unaudited interim results for the six months to 31 December 2025 showing solid top-line growth and stronger profitability, with revenue up 6% to $105.7m and double-digit increases in adjusted EBITDA, profit before tax and EPS. A...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.